CROI 2015 Program and Abstracts

Poster Listings

505 Detectable CSF Tat Despite Dual Compartment HIV Viral Suppression With cART Bruce Brew 1 ; Lucette A. Cysique 2 ; Simon Jones 4 ;Tory Johnson 3 ; Avindra Nath 3 1 St Vincent’s Hospital, Sydney, Sydney, Australia; 2 Neuroscience Research Australia, Sydney, Australia; 3 National Institute of Neurological Disorders and Stroke, Bethesda, MD, US; 4 St Vincent’s Centre for Applied Medical Research, Sydney, Australia 506 DNA Methylation Changes in HIV-Positive MenWith Cognitive Decline Jeremy Martinson ; Gregory Joseph; Lawrence Kingsley; JamesT. Becker Pitt Mens Study University of Pittsburgh, Pittsburgh, PA, US 507 HIV Induces Astrocyte Senescence and Is Reversed by Beta-Catenin Induction ChunjiangYu; Victoria Lutgen ; Lena Al-Harthi Rush University Medical Center, Chicago, IL, US 508 Wnts-Mediated Astrocyte/CD8+ T-Cell Interactions Impacting HIV Neuropathogenesis Maureen H. Richards 1 ; Melanie S. Seaton 1 ; Stephanie Kim 2 ; Srinivasa Narasipura 1 ; Lena Al-Harthi 1 1 Rush University Medical Center, Chicago, IL, US; 2 Brown University, Boston, MA, US 2:30 pm– 4:00 pm Pharmacokinetics, Pharmacodynamics, and Adherence 509 HIV-1 Attachment Inhibitor Prodrug BMS-663068: Model-Based Dose Selection Ishani Savant Landry 1 ; Li Zhu 1 ; Malaz Abutarif 1 ; Matthew Hruska 1 ; Brian M. Sadler 2 ; Maria Pitsiu 3 ; George J. Hanna 1 ; DavidW. Boulton 1 ; Richard Bertz 1 1 Bristol-Myers Squibb, Princeton, NJ, US; 2 ICON plc, Cary, NC, US; 3 ICON plc, Manchester, United Kingdom 510 Pharmacokinetic and Pharmacodynamic Evaluation of NNRTI IQP-0528 DuoGel™ in Macaques Lara E. Pereira 1 ; Pedro Mesquita 2 ; Anthony Ham 3 ;Tyana Singletary 4 ; Janet McNicholl 5 ; KarenW. Buckheit 3 ; Robert Buckheit 3 ; James M. Smith 5 1 LifeSource Biomedical LLC,, Moffett Field, CA, US; 2 Albert Einstein College of Medicine, Bronx, NY, US; 3 ImQuest BioSciences,, Frederick, MD, US; 4 Anyar Inc., Fort Walton Beach, FL, US; 5 US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US 511 Tenofovir PK in Adults With Renal Dysfunction on LPV/r and NNRTI-Based ART Tim R. Cressey 1 ; Anchalee Avihingsanon 2 ; Guttiga Halue 3 ; Prattana Leenasirimakul 4 ; Pra- ornsuda Sukrakanchana 5 ; AnthonyT. Podany 6 ; Courtney Fletcher 6 ; Gonzague Jourdain 5 ;Virat Klinbuayaem 7 ; Chureeratana Bowonwatanuwong 8 1 PHPT-IRD UMI 174 Chiang Mai University/Harvard School of Public Health, Chiang Mai, Thailand; 2 HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand; 3 Phayao Hospital, Phayao, Thailand; 4 Nakornping Hospital, Chiang Mai, Thailand; 5 Chiang Mai University, Chiang Mai, Thailand; 6 University of Nebraska Medical Center, Omaha, NE, US; 7 Sanpatong Hospital, Sanpatong, Thailand; 8 Chonburi Hospital, Chonburi, Thailand 512 Population Pharmacokinetics of CotrimoxazoleWest African HIV- Infected Children Claire Pressiat 1 ; Sihem Benaboud 2 ; Jean-MarcTreluyer 1 ;Véronique Méa-Assande 3 ; Caroline Yonaba 4 ; Sophie Dattez 5 ; DiarraYe 6 ;Yi ZHENG 1 ; Valeriane Leroy 5 ; Déborah HIRT 1 MONOD ANRS 12206 1 Paris Descartes University, EA 08, Paris, France; 2 Clinical Pharmacology Department, AP-HP, Paris Centre Hospital Group, Paris, France; 3 Avocatier Health Center, Abidjan, Côte d’Ivoire; 4 Department of Paediatrics, CHU Yalgado Ouedraogo, Ouagadougou, Burkina Faso; 5 Institute of Public Health, Epidemiology and Development (ISPED), University of Bordeaux, Bordeaux, France; 6 Department of Paediatrics, CHU Charles de Gaulle, Université de Ouagadougou, Ouagadougou, Burkina Faso TUESDAY, FEBRUARY 24, 2015 Session P-H1 Poster Session Poster Hall

513 ART Choice Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children Sunil Parikh 2 ; Norah Mwebaza 3 ; Richard Kajubi 3 ; Joshua Ssebuliba 3 ; Sylvia Kiconco 3 ; Liusheng Huang 1 ; Qin Gao 1 ; Abel Kakuru 3 ; Jane Achan 3 ; Francesca T. Aweeka 1 1 University of California, San Francisco, San Francisco, CA, US; 2 Yale University, New Haven, CT, US; 3 Makerere University College of Health Sciences, Kampala, Uganda 514 Exploring Long-Term Adherence Markers Using Hair and Dried Blood Spots in iPrEX OLE Monica Gandhi 1 ; DavidV. Glidden 1 ; Albert Liu 2 ; Peter L. Anderson 7 ; Howard Horng 1 ; Juan Guanira 3 ; Beatriz Grinsztejn 4 ; Suwat Chariyalertsak 5 ; Linda-Gail Bekker 6 ; Robert M. Grant 1 iPrEX OLE 1 University of California San Francisco, San Francisco, CA, US; 2 San Francisco Department of Public Health, San Francisco, CA, US; 3 Investigaciones Medicas en Salud, Lima, Peru; 4 Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil; 5 Chiang Mai University, Chiang Mai, Thailand; 6 University of Cape Town, Cape Town, South Africa; 7 University of Colorado, Denver, CO, US 2:30 pm– 4:00 pm Pharmacogenomics 515 UGT1A1 Genotype Predicts Bilirubin-Related Discontinuation of Atazanavir/Ritonavir Saran Vardhanabhuti 1 ; Heather J. Ribaudo 1 ; Raphael J. Landovitz 2 ; Igho Ofotokun 3 ; Jeffrey L. Lennox 3 ; Judith S. Currier 2 ; Lana M. Olson 4 ; DavidW. Haas 4 1 Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 2 UCLA Center for Clinical AIDS Research & Education, Los Angeles, CA, US; 3 Emory University School of Medicine, Atlanta, GA, US; 4 Vanderbilt University School of Medicine, Nashville, TN, US 516 ABCB1 Polymorphism Affects Tenofovir Exposure as Determined by Areas-Under-the-Time-Concentration-CurveWith 24-hour Intensive Pharmacokinetic Monitoring Sanjiv M. Baxi 1 ; Peter Bacchetti 1 ; Mardge Cohen 2 ; Jack A. Dehovitz 3 ; Kathryn Anastos 4 ; Stephen J. Gange 5 ; Mary A.Young 6 ; Monica Gandhi 1 ; Bradley Aouizerat 1 1 University of California San Francisco, San Francisco, CA, US; 2 John Stroger (formerly Cook County) Hospital, Chicago, IL, US; 3 State University of New York Downstate Medical Center, Brooklyn, NY, US; 4 Montefiore Medical Center, University Hospital for Albert Einstein College of Medicine, Bronx, NY, US; 5 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 6 Georgetown University, Washington, DC, US 517 Pharmacogenomics of Plasma Tenofovir Clearance and Change in Creatinine Clearance ValentineWanga 1 ; CharlesVenuto 2 ; Gene D. Morse 3 ; Edward A. Acosta 5 ; Eric Daar 4 ; David W. Haas 1 ; Chun Li 1 ; Bryan E. Shepherd 1 1 Vanderbilt University School of Medicine, Nashville, TN, US; 2 University of Rochester Medical Center, Rochester, NY, US; 3 State University of New York at Buffalo, Buffalo, NY, US; 4 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, US; 5 University of Alabama at Birmingham, Birmingham, AL, US 518 Variant ITPA Phenotypes Are AssociatedWith Increased Ribavirin Triphosphate Levels Leah C. Jimmerson 1 ;Thomas J. Urban 2 ; Eric Meissner 3 ; Ariel Hodara 1 ; Jacob A. Langness 4 ; Christina Aquilante 1 ; AimeeTruesdale 5 ; Fafa Baouchi-Mokrane 5 ; Michelle Ray 1 ; Jennifer J. Kiser 1 1 University of Colorado, Aurora, CO, US; 2 University of North Carolina, Chapel Hill, NC, US; 3 NIAID, NIH, Bethesda, MD, US; 4 University of Colorado Health, Aurora, CO, US; 5 Denver Health and Hospital Authority, Denver, CO, US 2:30 pm– 4:00 pm Drug-Drug Interactions 519 Interactions of Antiretroviral Drugs With the SLC22A1 (OCT1) Drug Transporter Darren M. Moss ; Neill Liptrott; Marco Siccardi; Andrew Owen University of Liverpool, Liverpool, United Kingdom Session P-H2 Poster Session Poster Hall Session P-H3 Poster Session Poster Hall

Poster Listings

43

CROI 2015